Lymphoma Working Party (LWP)
Study type:
Study number:
2021-N-02
Type of treatment:
Autologous
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Primary objective:
To assess the real-world impact of the use of BV and/or CPI-based salvage
therapy as bridge to autologous SCT for HL.
therapy as bridge to autologous SCT for HL.
Key inclusion criteria:
A. Age ≥ 18 years of age
B. Diagnosis: classical HL
C. Decision to use BV and/or CPI-based salvage therapy as bridge to
autologous SCT for HL
B. Diagnosis: classical HL
C. Decision to use BV and/or CPI-based salvage therapy as bridge to
autologous SCT for HL
Country:
All EBMT member countries
Principal investigator:
Ali Bazarbachi
EBMT Study coordinator:
Irma Khvedelidze
Study coordinator email:
irma.khvedelidze@upmc.fr
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results